A Message from the President
Dear Colleagues,
The 36th Annual Meeting & Pre-Conference Programs (SITC 2021) is just around the corner, and everyone at SITC is thrilled to welcome participants to Washington, D.C. and virtually, Nov. 10–14. There is much to look forward to at this year’s program, including exciting science, hot topic symposia and debate-style sessions. As always, the meeting is a wonderful opportunity to catch up with old friends and colleagues while providing a chance to expand our professional network.
With the impending 36th Annual Meeting, I took advantage of a timely opportunity. I invited the Annual Program Committee Chair, Padmanee Sharma, MD, PhD of The University of Texas MD Anderson Cancer Center, to sit down with me for this month’s fireside chat. Dr. Sharma gave a great preview of the topics to be discussed at the meeting, and we also had a chance to converse on several other important subjects.
Our chat explores her stellar work within the genitourinary field, how she has come to be a critical member of SITC, and a trailblazing member of the tumor immunology community worldwide. We revisit the very first neoadjuvant trial with anti-CTLA4, designed and conducted by Dr. Sharma, which laid the foundation for a neoadjuvant approach to immune checkpoint therapy. Looking to the future, Dr. Sharma shares her vision for next generation biomarkers and offers reflections on the future of immunotherapy for genitourinary cancers.
Our exchange left me inspired, and I want to thank Dr. Sharma again for sitting down with me this month and for her time and effort put towards the 36th Annual Meeting. I look forward to seeing all of you in a few weeks at the meeting!
Sincerely,
Patrick Hwu, MD
SITC President
Register Now for the 36th Annual Meeting & Pre-Conference Programs
Registration is now open for the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021)! SITC 2021 takes place Nov. 10–14, 2021, at the Walter E. Washington Convention Center in Washington, D.C., and virtually. Click here to register.
Planning to attend SITC 2021 in-person? Our goal is to have a safe and meaningful conference. To help manage the safety of all attending, proof of full vaccination for COVID-19 will be required for all in-person meeting attendees.
To uphold this requirement, SITC has established an easy vaccination validation process. To verify vaccination status, registered participants will need to sign an event waiver form, complete a health screening questionnaire and upload proof of a vaccination record. When completing this short process, it is critical that you use the e-mail address associated with your SITC 2021 registration. For a smooth experience onsite at SITC 2021, SITC highly recommends completing the electronic vaccination validation process as soon as possible. Please watch for an e-mail from SITC Education within the next week, which will detail the full process and instructions.
We are excited and committed to offering a safe, in-person experience, and we will be adhering to the local safety guidelines and regulations. For the latest information on requirements for Washington D.C., click
here.
For more information about the safety measures in place for in-person attendance, click
here and for information about attending SITC 2021 in person and virtually, visit the
FAQ page.
SITC 2021 Schedule-at-a-Glance
Nov. 10, 2021
Nov. 11, 2021
Nov. 12-14, 2021
Additional SITC 2021 Activities
Support SITC 2021
SITC offers a number of ways to promote your product or service. SITC 2021 will be presented as a hybrid meeting, which means we have innovative in-person and virtual solutions to meet your marketing and branding needs.
Contact development@sitcancer.org or (414) 271-2456 for more information and to discuss customization options.
Advances in Cancer ImmunotherapyTM (ACI) Educational Series
Join SITC for its newly redesigned Advances in Cancer Immunotherapy™ (ACI) educational series, with each program offering focused clinical education on a disease state or topic. Attendees of these half-day innovative programs will have the opportunity for in-depth training in immunotherapy treatment from leaders in this specific field. The ACI program will also feature a discussion of closed cases submitted from attendees to hear guidance and insights from expert faculty. This meeting is certified for CME, CNE, CPE, and MOC credits.
ACIs are free for healthcare professionals in the clinical setting, students and patient advocates.
Register today for the upcoming ACI programs!
Series Schedule:
ACI: A Focus on Genitourinary Cancers (Virtual Only)
Wednesday, Oct. 27, 2021, 12–4 p.m. ET
ACI: A Focus on MSI-High and TMB-High Cancers (Virtual Only)
Wednesday, Nov. 3, 2021, 5–9 p.m. ET
ACI: A Focus on Gastrointestinal Cancers (Virtual Only)
Wednesday, Nov. 17, 2021, 12–4 p.m. ET
ACI: A Focus on Gynecologic Cancers (Virtual Only)
Tuesday, Dec. 14, 2021, 12–4 p.m. ET
ACI: A Focus on Hematologic Malignancies (Virtual Only)
Wednesday, Feb. 2, 2022, 7–11 p.m. ET
ACI: A Focus on Biomarkers (Hybrid)
Thursday, March 24, 2022, 7–11 p.m. ET
ACI: A Focus on Toxicity Management (Hybrid)
Thursday, April 28, 2022, 1–5 p.m. ET
Registration Now Open Attend the Hybrid 2022 SITC Cancer Immunotherapy Winter School
Jan. 24–28, 2022 · Austin, TX · In Person and Virtual
SITC is pleased to host its fourth annual and first hybrid Cancer Immunotherapy Winter School, a comprehensive cancer immunotherapy education program, Jan. 24–28, 2022. This program will be offered in a hybrid format with opportunities to participate in Austin, TX and virtually! We are proud to present the best in cancer immunotherapy education taught by leading experts in the field, whether you plan to travel or attend remotely.
Taught by leading experts in the field, this program provided a deep understanding of the core principles of tumor immunology and cancer immunotherapy as well as developing areas in the field including biomarker technology, validation and clinical integration; clinical trial design, data analysis and considerations for combination therapies.
Program Organizers
- Catherine Bollard, MBChB, MD – Children’s National Hospital
- Christian Capitini, MD – University of Wisconsin-Madison
- Daniel Powell, PhD – University of Pennsylvania